QUOTED. Aug. 7, 2018. Bryan Hanson.
Device-maker Zimmer Biomet confirmed on a July 27 earnings call that its US FDA quality systems compliance challenges aren't over quite yet – in fact, the firm received additional observations after the agency's most recent inspection of its Warsaw, Ind., facility. During the call, President and CEO Bryan Hanson described his approach to resolving FDA's concerns as "an open checkbook." See what else he said here.
"If resources are needed, the resources are retained and we’re going to move this thing forward." –Bryan Hanson, president and CEO, Zimmer Biomet
- Find out more:Zimmer Confirms Ongoing FDA Attention To Warsaw Plant
Click here for a free trial of Medtech Insight